NCT01033292View on ClinicalTrials.gov

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Ovarian Cancer
Interventions
DRUG

BSI-201

IV infusion, 5.6 mg/kg

Trial Locations (1)

02114

Massachusetts Ceneral Hospital, Boston

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01033292 - A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter